Astellas Sees Further FDA Action On Prograf MR In Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.
You may also be interested in...
Astellas Responds To "Approvable" Letter For Prograf MR Kidney Transplant Claim
Astellas Pharma has responded to an FDA "approvable" letter for use of the once-daily immunosuppressant Prograf MR (tacrolimus modified-release) to prevent rejection of kidney transplants, the Japanese firm announced Sept. 19
Astellas Responds To “Approvable” Letter For Prograf MR Kidney Transplant Claim
Tokyo-based pharma is still examining what action to take regarding a “not approvable” letter for a heart transplant indication.
Astellas Responds To “Approvable” Letter For Prograf MR Kidney Transplant Claim
Tokyo-based pharma is still examining what action to take regarding a “not approvable” letter for a heart transplant indication.